TRAW
Traws Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.37
−0.76%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +131.1%
- EBITDA
- +89.3%
- EBIT
- +63.8%
- Net income
- +116.8%
- EPS
- +102.4%
- Free cash flow
- +30.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026